RT Journal Article
SR Electronic
T1 Brain-derived Tau for Monitoring Brain Injury in Acute Ischemic Stroke
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.18.23298728
DO 10.1101/2023.11.18.23298728
A1 Naomi Vlegels
A1 Fernando Gonzalez-Ortiz
A1 Nicoló Luca Knuth
A1 Nada Khalifeh
A1 Benno Gesierich
A1 Franziska Müller
A1 Philipp Müller
A1 Matthias Klein
A1 Konstantinos Dimitriadis
A1 Nicolai Franzmeier
A1 Thomas Liebig
A1 Marco Duering
A1 Paul Reidler
A1 Martin Dichgans
A1 Thomas K. Karikari
A1 Kaj Blennow
A1 Steffen Tiedt
YR 2023
UL http://medrxiv.org/content/early/2023/11/19/2023.11.18.23298728.abstract
AB The evolution of infarcts varies widely among patients with acute ischemic stroke (IS) and influences treatment decisions. Neuroimaging is not applicable for frequent monitoring and there is no blood-based biomarker to track ongoing brain injury in acute IS. Here, we examined the utility of plasma brain-derived tau (BD-tau) as a biomarker for brain injury in acute IS. We conducted the prospective, observational Precision Medicine in Stroke [PROMISE] study with serial blood sampling upon hospital admission and at days 2, 3, and 7 in patients with acute ischemic stroke (IS) and for comparison, in patients with stroke mimics (SM). We determined the temporal course of plasma BD-tau, its relation to infarct size and admission imaging-based metrics of brain injury, and its value to predict functional outcome. Upon admission (median time-from-onset, 4.4h), BD-tau levels in IS patients correlated with ASPECTS (ρ=-0.21, P<.0001) and were predictive of final infarct volume (ρ=0.26, P<.0001). In contrast to SM patients, BD-tau levels in IS patients increased from admission (median, 2.9 pg/ml [IQR, 1.8-4.8]) to day 2 (median time-from-onset, 22.7h; median BD-tau, 5.0 pg/ml [IQR, 2.6-10.3]; P<.0001). The rate of change of BD-tau from admission to day 2 was significantly associated with collateral supply (R2=0.10, P<.0001) and infarct progression (ρ=0.58, P<.0001). At day 2, BD-tau was predictive of final infarct volume (ρ=0.59, P<.0001) and showed superior value for predicting the 90-day mRS score compared with final infarct volume. In conclusion, in 502 patients with acute IS, plasma BD-tau was associated with imaging-based metrics of brain injury upon admission, increased within the first 24 hours in correlation with infarct progression, and at 24 hours was superior to final infarct volume in predicting 90-day functional outcome. Further research is needed to determine whether BD-tau assessments can inform decision-making in stroke care.Competing Interest StatementKB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. TL protors and consults for Stryker, phenox, Acandis, and has in the past received suport for travel and service related fees from Medtronic, Pfizer, Cerus Endovascular, Sequent, and Microvention. NV, NLK, MD, and ST report a patent on the use of BD-tau. No other disclosures were reported.Funding StatementF.G.-O. was funded by the Anna Lisa and Brother Bjornssons Foundation and Emil och Maria Palms Foundation. S. T. was supported by grants from the Corona foundation (S199/10081/2020), the Leducq foundation (21CVD04), and the Friedrich-Baur-Stiftung (52/23). TKK was supported by grants P30 AG066468, RF1 AG052525-01A1, R01 AG053952-05, R37 AG023651-17, RF1 AG025516-12A1, R01 AG073267-02, R01 AG075336-01, R01 AG072641-02, and P01 AG025204-16 from the National Institutes of Health; the Swedish Research Council (Vetenskapradet; 2021-03244); the Alzheimers Association (AARF-21-850325); the Swedish Alzheimer Foundation (Alzheimerfonden); the Aina (Ann) Wallstroms and Mary-Ann Sjobloms stiftelsen; and the Emil och Wera Cornells stiftelsen. KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), Hjarnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), and the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethic committee of LMU Munich gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data produced in the present study are currently not available if not already presented in the manuscript.